CCA
KRTX

Catalyst Capital Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Catalyst Capital Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-310
Closed -$6K – 499
2019
Q2 		$6K Buy
+310
New +$6.21K ﹤0.01% 382

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Catalyst Capital Advisors's KRTX Position: Q3 2019 in Review

Catalyst Capital Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2019, closing a stake of 310 shares — an estimated $6K sold.

Catalyst Capital Advisors first reported a position in KRTX in Q2 2019 and held it in 1 quarter. The position peaked at $6K in Q2 2019. 50 funds tracked by Wall St. Rank hold KRTX as of Q3 2019.

  • Catalyst Capital Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 310 Karuna Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $6K.
  • Catalyst Capital Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Catalyst Capital Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $6K in Q2 2019.
  • 50 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Catalyst Capital Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.